R1 RCM’s (RCM) Outperform Rating Reaffirmed at Robert W. Baird

Robert W. Baird restated their outperform rating on shares of R1 RCM (NASDAQ:RCM) in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a $18.00 price objective on the healthcare provider’s stock.

Other analysts also recently issued research reports about the company. Canaccord Genuity Group cut their price objective on R1 RCM from $16.00 to $15.00 and set a buy rating on the stock in a report on Thursday, May 9th. Morgan Stanley reissued an overweight rating and issued a $17.00 price target on shares of R1 RCM in a research note on Tuesday, March 26th. Truist Financial reissued a hold rating and issued a $16.00 price target on shares of R1 RCM in a research note on Monday, April 1st. Cantor Fitzgerald reissued an overweight rating and issued a $20.00 price target on shares of R1 RCM in a research note on Tuesday. Finally, Royal Bank of Canada reissued an outperform rating and issued a $19.00 price target on shares of R1 RCM in a research note on Friday, June 28th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $16.00.

R1 RCM Stock Performance

RCM stock opened at $10.90 on Tuesday. The company has a market capitalization of $4.59 billion, a P/E ratio of -136.25 and a beta of 0.85. The company has a 50-day simple moving average of $12.42 and a 200 day simple moving average of $11.90. R1 RCM has a fifty-two week low of $8.87 and a fifty-two week high of $18.70. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.78.

R1 RCM (NASDAQ:RCM) last issued its quarterly earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). R1 RCM had a negative return on equity of 1.16% and a negative net margin of 1.39%. The business had revenue of $603.90 million during the quarter, compared to the consensus estimate of $612.88 million. The company’s revenue was up 10.7% compared to the same quarter last year. Sell-side analysts predict that R1 RCM will post -0.17 earnings per share for the current fiscal year.

Institutional Trading of R1 RCM

Large investors have recently made changes to their positions in the business. Voss Capital LLC boosted its holdings in R1 RCM by 553.9% in the fourth quarter. Voss Capital LLC now owns 7,125,000 shares of the healthcare provider’s stock valued at $75,311,000 after acquiring an additional 6,035,340 shares during the last quarter. Norges Bank acquired a new position in R1 RCM in the fourth quarter valued at about $42,539,000. P2 Capital Partners LLC lifted its stake in R1 RCM by 70,366.3% in the fourth quarter. P2 Capital Partners LLC now owns 3,535,294 shares of the healthcare provider’s stock valued at $37,368,000 after buying an additional 3,530,277 shares during the period. Boston Partners lifted its stake in R1 RCM by 4,976.6% in the first quarter. Boston Partners now owns 2,570,371 shares of the healthcare provider’s stock valued at $32,784,000 after buying an additional 2,519,739 shares during the period. Finally, Sea Cliff Partners Management LP acquired a new position in R1 RCM in the fourth quarter valued at about $18,459,000. Institutional investors own 61.10% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.